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A. The blood—brain barrier; anatomic, physiologic, 
and pharmacologic concepts. 
The brain appears to be in a class by itself insofar 
as tne penetration of compounds is concerned. It has been 
observed that there is a selective penetration of substances 
from the blood into the cerebrospinal fluid in mammals. 
Normal constituents of the blood may be almost totally 
excluded from the cerebrospinal fluid or they may appear 
in concentrations similar to tnose in plasma^l). Alterations 
in the plasma concentrations of oxygen, glucose, urea, sodium 
ions, and chloride ions, for example, are followed by com¬ 
parable alterations in tne concentrations of these substances 
in the cerebrospinal fluid. No substances are found in the 
cerebrospinal fluid which are not normally found in the blood(2). 
Mesobilirubin, on the other hand, does not penetrate into the 
brain of the adult, although tnere is apparently no barrier 
to the entrance of this substance into the brain of the 
newborn infant(3). This forms the basis for the development 
of kernicterus(pigmentation of the basal ganglia of the 
brain by bilirubin) in infants in whom the serum indirect- 
reacting bilirubin level exceeds 20 mg/100 ml, as in erythro¬ 
blastosis fetalis. Adults with levels of serum bilirubin 
high enough to produce clinical jaundice never develop 
kernicterus, altnougn the serum bilirubin level may exceed 
the above value. 
Similarly, drugs introduced into the blood may penetrate 
into the brain without difficulty or may pass into the central 
nervous system slowly or not at all, even thougn penetrating 
other organs with ease. 
The boundary between the brain and the blood is generally 
called the blood-brain barrier, or hemoencephalic foarrier(4—8)• 
It should be noted that this barrier does not lie between 
brain cells and tne fluid surrounding them, since drugs are 
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known to penetrate the cells of tae brain as readily as 
those of any other tissue(9). Tne barrier seems to lie 
between plasma and the extracellular fluid of the central 
nervous system(lO). It will be assumed here that the 
cerebrospinal fluid and the extracellular fluid of the 
central nervous system constitute a continuum, and that 
measurements made on the former reflect accurately changes 
occuring in the latter(il). Mayer has furnished evidence 
which supports this concept(12). Measurements of the influx 
of drugs into the central nervous system at different stages 
of equilibrium indicate that the blood-cerebrospinal fluid 
and blood—brain barriers are essentially the same with 
respect to foreign compounds. Substances such as barbital, 
acetanilid, and N-acetyl-4-aminoantipyrine, which do not 
appreciably bind onto cellular components, enter the cerebro¬ 
spinal fluid at tne same rate as into brain water; although 
they penetrate at a very slow rate into the central nervous 
system. With thiopental, however, the concentration in 
brain water is much higher than in cerebrospinal fluid. 
The high brain/cerebrospinal fluid ratio observed here is 
not due to a hign concentration gradient of drug between 
brain and cerebrospinal fluid but to reversible binding 
of the drug onto tissue components in the brain. Broman 
has also furnished considerable evidence substantiating 
the hypothesis that the cerebrospinal fluid and the extra¬ 
cellular fluid of tne central nervous system reflect a 
continuum(10). The blood-brain barrier concept is supported 
by anatomic, physiologic, and pharmacologic evidence. 
The first consideration is that of the location of 
the barrier. In experiments described by Brodie and liogben 
the highly lipid-soluble drug amidopyrine penetrated into 
the brain so rapidly that it must have entered from blood 
capillaries in all parts of the brain(lO). The concentration 
of this drug was uniform in various parts of the brain at 
any given time from two minutes to one hour after administration. 
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is also substantiated by the even distribution of N—acetyl— 
4-aminoantipyrine in cerebrospinal fluid, cerebral cortex, 
cerebellum, brain stem, and medulla shortly after drug 
administration(12j. From tnese results it may be inferred 
tnat the flow of drugs into cerebrospinal fluid is primarily 
by way of the choroid plexus and perhaps from pial vessels, 
whereas drugs pass into brain tissue directly from brain 
capillaries(13). a similar conclusion as to the uniformity 
of the blood-brain barrier to bromide, iodide, and thiocyanate 
ions was reached by Wallace and Brodievl4). It must be 
emphasized, however, that for substances such as g;lucose 
and sodium which enter the central nervous system by 
specialised transfer mecnanisms, the rates of influx may 
well vary in different parts of the central nervous system. 
Blood-cerebrospinal fluid partitions seem to be more 
complex structurally than those separating blood vessels 
from extracellular fluid elsewhere in tne body. Capillaries 
in the choroid plexuses of the brain, from which the cerebro¬ 
spinal fluid is evolved, are separated from the cerebrospinal 
fluid by a layer of ependymal cells. Elsewhere in the central 
nervous system tne endotnelium of capillaries appears to be 
covered by a continuous sneath of neuroglial(astrocytic) 
cytoplasmic processes. Materials from the blood may thus 
be required to pass through the glial cells before they 
become available to the neurons(2,15). Pernaps these unique 
features of cerebrospinal blood vessels are related to the 
special physiological relations between the bloodstream 
on one hand, and the cerebrospinal fluid and interstitial 
fluid of tne central nervous system on the other. 
Most of the exchange of materials between the brain 
and the rest of the body occurs by this route, including 
both normal metabolites and administered substances. 
Exclusion appears to be exerted just beyond the cerebral 
capillaries. Microscopic observation of these capillaries 
after intravenous injection of colored and fluorescent 
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as far as the cells of the capillaries, but not to the 
glial cells which surround them. The electron microscopic 
ultrastructure of this perivascular space has been elucidated 
only recently(16). 
It is noteworthy that differential permeability is 
seen to appear in tne brain at a stage in development when 
the lining of glial processes also appears— and again, that 
certain limited areas of the brain, xn which the glial cell 
lining is absent, do not show a barrier such as is found 
elsewuere in the brain. These areas, the hypothalamus, 
pituitary, and pineal, differ from the rest of the brain 
in that they are readily colored by intravenously administered 
vital dyes which do not penetrate otner jxarts of the brain; 
32 
and intravenously administered P appears in these locations 
much more rapidly than in other parts of the brain(17,18,19). 
The blood-brain barrier may be functionally different in 
tnese instances. It is interesting to note that all three 
of tnese regions have a neuroendocrine function. 
There are several physiological lines of evidence 
favoring the existence of a blood—brain barrier. As mentioned 
previously, bile pigments do not penetrate into the brain of 
the adult regardless of their blood concentration; whereas 
the development of basal ganglia pigmentation(kernicterus) 
is presumably due to immaturity of this barrier during the 
first week of life. 
The permeability of the barrier is occasionally altered 
in persons with brain tumors. This permits localization of 
such tumors with iodofluorescein, which does not penetrate 
the blood-brain barrier in normal individuals(20). Similarly, 
131 
dyes containing radioactive iodine(I ) can be used to 
localize brain tumors, using appropriate detection devices{21). 
Immunological tecnniques have snown that large molecules, 
such as proteins, are excluded from the brain(15/. Glucose 
is one of the relatively few circulating nutrients capable 
of passing from the blood into the brain and of being 
effectively used by tne cells of the central nervous system; 
. 
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it appears to be actively transported^^). Radioactive ions 
introduced into the blood appear in the cerebrospinal fluid 
only after a considerable delay, indicating that the normal 
exchange of ions is exceedingly slow. For example, P^“ 
levels in brain tissue reach a peak within one hour after 
direct introduction into the cerebrospinal fluid, whereas 
12 to 24 hours are required after intravenous administration(23) 
Central nervous system tissue has a rapid phosphorous metabolism 
but its access to vascular phosphate is normally severely 
limited(24j. In pathological conditions such as inflammation 
or following brain laceration, phosphate is noted to enter 
the brain rapidly, in contradistinction to the above. 
Sodium and culoride ions are not found in the cerebro¬ 
spinal fluid in the quantities predicted by the Gibbs-Donnan 
24> 
theory of membrane equilibria. Radioactive sodium(Na ) 
enters the brain slowly after intravenous administration, 
the nhalf equilibrium value" being 95+ 6 minutes(25). This 
is contrasted with the time required for equilibration with 
the sodium in the rest of the body, which is measured in 
minutes rather than hours. These observations, together 
with the fact that administered radioactive sodium enters 
cells in the central nervous system slowly, give some 
insight into the nature of the bloou-brain barrier(15,26). 
A similar effect is noted upon administration of radio¬ 
active cnloride ion, in that penetration into the brain 
is relatively slow, Tnis emphasizes that tue "barrier" 
is specific to exchange with the blood(27j. 
Many other ionized substances penetrate only slowly 
into the brain from the blood. Ferricyanide given intra- 
ventricularly gives rise to marked central effects 
terminating in convulsionsj this reaction does not occur 
after intravenous administration. Bromide, iodide, and 
thiocyanate ions also penetrate at a very slow rate, 
nmong several classes of substances, basic compounds 
usually penetrate into the brain more rapidly than acidic 
ones, although exceptions are known. In 18S7 Fhrlich injected 
. 
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acidic and basic aniline dyes into experimental animalsj 
he observed that the basic substances, including methylene 
blue, reached the brain much as they did other organs of 
the body(28). 
The brain in very young animals is less selective in 
this respect. The brain of tae newborn mouse, for example, 
was stained by trypan blue, whereas the adult brain was 
not. The impermeability of the adult human brain to 
biiirubi'n illustrates tne x>ro^eci'ive value of relative 
impermeability to acidic substances, suggested also in 
relation to many synthetic drugs of this nature. 
Insulin does not pass the blood-brain barrier and 
is therefore excluded from the central nervous system. 
Since the central nervous system contains very little 
glycogen, it requires a continuous supply of available 
glucose in the extracellular fluid^SO). 
Glutamine penetrates the blood—brain barrier, although 
glutamic acid does not. Since the barrier seems to apply 
to exit of substances from the central nervous system as 
well as to entry, the glutamic acid formed within the 
brain cannot leave without being first combined with 
ammonia to form glutamine. This reaction is catalysed 
by glutamine synthetase, an enzyme occurring in brain, 
retina, and kidney, and requiring magnesium ion and ATP 
as cofactors(20). 
The trypanocide suramin, which is normally relatively 
non-toxic, becomes highly toxic when injected into the 
subarachnoid space, illustrating the teleological advantage 
of the barrier in excluding certain foreign substances. 
Binding of tne drug to serum proteins also contributes to 
the difference in its effect when given by the two routes, 
in this particular case. 
Calcium, magnesium, or potassium excess or depletion 
has a deleterious effect on vasomotor and respiratory reflexes. 
By means of the blood-brain barrier the central nervous 
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environment. Perhaps certain substances, such as potassium, 
are confined bj this barrier to the central nervous system, 
where they are re-used by neurons and not swept away by 
blood(29). Tscnirgi has suggested that the barrier serves 
to regulate tne environment of the cells of the central 
nervous system(20,23). Homeostatic mechanisms may be even 
more highly developed in the brain than elsewhere in the body. 
f>» Folic acid and its antimetabolites; clinical uses of amethopterin, 
Folic acid., or pteroylglutamic acid, was first implicated 
in human nutrition in 1931, when Wills described a macrocytic 
anemia in Hindu women in Bombay, usually associated with 
pregnancy, which responded to autolyzed yeast therapy(30). 
Wills and associates reproduced this anemia in monkeys by 
feeding tnem a diet similar to that of their human patients(31). 
It was also snow that this macrocytic anemia responded to 
crude liver extract, out not to the fraction effective in 
the treatment of pernicious anemia(32). The responsible 
fraction came to be know as the "Wills factor." Day et al 
in 1935 described an anemia in monkeys correctable by dried 
brewer's yeast, but not by any of the B complex vitamins 
know at that time(33). The unknown factor involved was 
called vitamin M. Stokstad and Manning in 1938, and Eogan 
and Parrott in 1940 described a syndrome in chicks characterized 
by anemia and growth failure; this was correctable by many 
substances, including yeast. The factor involved was labelled 
vitamin B (34,35). 
c 
Several microbiologists in the years 1940 to 1945 
identified a substance necessary for tne growth of Lactobacillus 
casei and called it the L. casei factor(30,37). Mitcue 11 
et al in 1941 isolated from spinacn an acid which supported 
growth ox both Strep, faecalis and _L. casei; tne leafy 
vegetable origin of this substfeuace led to the name iolic 
acid(38;. During the next several years it was realized 
that the L. casei factor, vitamin M, and vitamin B were 
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by the small yields of material available from natural 
sources, such as yeast or liver. The discovery by tne 
Lederle Laboratories of an organism -which synthesized the 
factor made available a sufficient quantity of tae substance 
to enable Angier et al in 1946 to identify it chemically as 
a conjugate of pteroylglutamic acid(42,43). Angier then 
synthesized the vitamin, and it -was found that the 
hematological but not the neurological lesions(subacute 
combined degeneration) of Addisonian pernicious anemia 
could be alleviated by the vitamin(43). 
Folic acid is apparently not active as such but is 
the precursor of the active vitamin, now known as folinic 
acid or citrovorum factor, since it is a growth requirement 
for Leuconoctoc citrovorum(44). The biological conversion 
involves reduction of the folic o,cid molecule and intro¬ 








This conversion is accomplished primarily in the liver 
and bone marrow(45,46). The action of the folic acid antagonists 
to be described later is to block this conversion and thereby 
to interfere with the important metabolic actions of the 





and its formyl derivative, foiinic acid, act as prosthetic 
groups in enzyme systems- involved in tne formation and 
utilization of active one-carbon units, the so-called 
"formate" pool(47,48). In particular, folic acid has 
been shown to be important in methylation of the pyrimidine 
ring to produce thymine and in the introduction of the 
2- and 8- carbon atoms into the purine ring. Its importance 
in nucleic acid metabolism is easily apparent. 
Certain analogs of folic acid block the important 
actions of folic acid in nucleic acid metabolism and cyto- 
poiesis. Studies by Franklin et al in 1947 showed that 
administration to animals of a crude methylated derivative 
of folic acid resulted in the signs and symptoms of folic 
acid deficiency, among which were slow growth, anemia, 
and leukopenia(49). Some degree of hematological remission 
was found when this antimetabolite was used in tne treatment 
of leukemia. Interestingly, the administration of folic 
acid resulted in an exacerbation of the disease(50). Present 
pharmacologic interest centers around two active antimetabolites 
of folic acid: 4—aminopteroylglutamic acid(aminopterin), and 
4-amino-N1 -methylpheroylglutamic acid(amethopterin, or Methotrexate®). 
A great variety of analogs of pteroylgluiamic acid have 
been synthesized and tested for possible growth innibitory 
capacity against L. casei, as a screening zsetnod for possible 
use in man. 
10 
Cosulich et al prepared N - ethyl, butyl, carboxymethyl, 
benzyl, axid phenacylpteroic acids, and showed these to be 
of a lower order of antagonist activity as compared to 
methylpteroylglutamic acid and methylpteroic acid(51). 
The same group prepared 9—methyl and 9,10—dimethyl— 
pteroylgluiamic acids and their 4-amino derivatives, and 
showed that they exhibited antagonism for pteroylgluiamic 
acid in the growth of Sh faecalis 11.(52). 
Seeger et al prepared several 4—amino derivatives of 
pteroylgluiamic acid with growtn antagonism activities of 
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from 1.6 to 15.3, as compared to 1.0 for half-maximum 
inhibition of growtn of J3. faecalis R. (53). 
Wright et al replacea the glutamic acid moiety with 
several other amino acids and prepared the 4-amino derivatives 
of these substances. Bacterial growtn inhibition was not 
significant, however(54)» 
Roth et al found that 4—(dimethylaminoj-pteroylglutamic 
10 
acid and its N - derivative had- a much lower antagonist 
activity for Si. faecalis R. than does 4—amiaopteroylglutamic 
acid. Also the toxicity was less for experimental animals(55), 
Cosulich et al tested 3’,5’-dihalopteroyI derivatives 
for activity against S. faecalis R. and found that 
31,5'-dibromo-4—aminopteroylglutamic acid and 3’,5’-diculoro— 
4—aminopteroylglutaiaic acid had slight growth antagonism 
activities as compared to aiuetnopterin(56). 
Tais same group has syntnesized many other derivatives, 
including 2-alkylamino derivatives, 3’—chioro and o'-bromo 
derivatives of ametnopterin, and 4-alkoxy derivatives(57,58,59). 
In addition various tetranydro compounds with a N^-formyl— 
pteroylglutamic acid nucleus corresponding to the above 
derivatives have been prepared, analogous to folinic acid(60,61,62). 
Goldin et al showed that 3’,5’—diculoroamethopterin has 
10 
marked activity against L1210 leukemia in mice(63). N “-ethyl- 
amethojiterin was shown to have the same antileukemic effectiveness 
as does amethopterin. 
Collier and Phillips investigated 2,4—diaminopteridines 
as folic acid antagonists, and reported experiments with 
6,7—dimethyl, diethyl, diphenyl, di-n—butyl, di-d-propyl, etc., 
derivatives, in which these compounds were tested for growth 
inhibition with Leuconostoe citrovorum cultures to which 
folinic acid had been added. The amount of growth was 
detected by titration of tne acid produced in the medium. 
Peak activity was found with di-sec—butyl, di-P-propyl, and 
1,-n-propylindolo(21,3')- derivatives. Slight activity was 
shown by 6, 7-dimethyl and 6,7-diphenyl derivatives(64). 
... . 
* . < 
... 
' > . 3 * . 
• ’ , . J. i 
• ** c • ■' W unvo’t f-r ;• ,$j 
1 iOT j. ’ 
• 
_ i i 
• 
i l 









■ - • 
‘ ?3*J 
. . 
« \ \ 
■ 0 0 
’ 
It is of interest that certain antimalarials, such as 
pyrimethamine, possess antifolic activity. Some antifolics 
are also potent antimalarials. In the above series of 
compounds tested by Collier and Phillips there vms no 
correlation between antifolinic activity, as evaluated with 
Leuconostoc citrovorum, and ability to suppress Plasmodium 
berghei infections of mice(64). 
Greenberg reported that 7-methylpteroylglutamic acid, 
9—methylpteroylglutaaic acid, 2,4—diaminopteroj. laspart ic 
acid, and methylpterbylglutamic acid completely reversed, 
the antiraalarial activity of sulfadiazine against JP. gallinaceuia 
in chicks(65). 
Many other analogs are capable of growth innibition in 
microorganisms which require folic acid in their medium; in 
general, however, only the 4—amino analogs(amethopterin and 
aminopterin) have proved to be highly active in mammals, 
including xnan{66,67,68)0 
The lives of mice implanted experimentally with leukemia 
can be prolonged by the administration of folic acid antagonists, 
such as aiaetnopterin(,69). This provides the experimental basis 
for the therapeutic use of these drugs in human leukemias, 
especially the acute leukemias of childhood. Burchenal, as 
early as 1951, cited many cases of good clinical and hematological 
remissions, as well as partial remissions, in patients treated 
with araethopterin(70). 
Skipper et al demonstrated in mice that a definite 
relationsnip exists between tne effectiveness of amethopterin 
and the size of the neoplastic population at tne time of 
initiation of therapy(71). For L121G leukemia in mice the 
effectiveness of amethopterin as a "curative agent" was 
inversely related to the tumor cell population at the time 
of initiation of therapy. It is of interest to note that 
folinic acid, or citrovorum factor, antagonizes this 











. • \ . 
. 
/. x O 
■ . < 
. 
: • 9 . 







If leukemic cells from animals treated with folic acid 
antagonists are injected into susceptible recipients, 
increasing tolerance to the action of the antimetabolite 
develops with successive transfers until the drug eventually 
exerts no chemotherapeutic action. This same type of 
refractory state develops in clinical leukemia after 
repeated courses of amethopterin. 
In a ten year old child with lymphosarcoma, studied 
by Y/hiteside et al, amethopterin was administered in an 
oral dose of 2.5 mg daily for seven days, followed by a 
single dose of 10 mg orally(73). Amethopterin appeared in 
the cerebrospinal fluid one hour after the last dose, 
reaching a level of 15 mpg/rnl in three hours, and falling 
to 2 mpg/rnl in 18 hours. The serum level of ametnopterin 
before the last "priming" dose was 2 mpg/ml; thirty minutes 
following the last dose it was 900 mpg/ml, and by 18 nours 
it had fallen to 5 mpg/ml. It is thus seen that the cerebro¬ 
spinal fluid drug level declines fairly rapidly after 
intrathecal administration, so that the concentration present 
after 24 hours exerts a negligible therapeutic effect. 
Indeed, Welch has pointed out tnat the limitation on dosage 
by the intrathecal route appears to be ine rate at which 
the drug leaves the cerebrospinal fluid to enter the 
systemic circulation, thereby affecting such sensitive 
tissues as the bone marrow and the mucosa of the gastrointestinal 
tract(74). 
Five patients with neurological symptoms of leukemia 
and lymphosarcoma improved markedly on doses of 0.1 to 0.5 mg/kg 
of intrathecal amethopterin^73). Neurological remissions 
began one week after the instillation and lasted six weeks. 
From 14fo to 33fo of the intrathecal dose was excreted, in 
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Chorioncarcinoma, or chorionepithelioma, is an 
uncommon highly malignant tumor of fetal trophoblastic 
tissue, occurring in pregnant or postpartum women. The 
presence of this tumor lormerly invoked an almost hopeless 
outlook for the patient, since metastasis usually has 
occurred before the primary tumor is discovered. Most 
women afflicted with this tumor die within one to two 
years of onset. Cnorioncarcinoma also exists as a rare 
testicular tumor in males and carries a similar prognosis 
in tnis instance. The treatment in former years has been 
wide total Hysterectomy and removal of all metastases that 
can be found and removed surgically. Chorioncarcinoma 
is not radiosensitive. The elaboration of chorionic 
gonadotrophin is cnaracterisiic of this tumor, and the 
finding of high titers of this substance in the urine of 
affected patients is useful in diagnosis^75). 
With the introduction of therapy with amethopterin 
the outlook for patients with this tumor has been somewhat 
improved(76,77). Hertz et al noted that inhibition of 
estrogen-induced growth in the chick oviduct and monkey 
uterus occurred when the animals were maintained on a 
folic acid deficient diet or treated with antagonists of 
either folic acid or adenine(78). Li, hertz, and Spencer 
studied the effect of ametnopterin on urinary excretion 
of chorionic gonadotrophin and on the clinical course of 
two patients with chorioncarcinoma and one patient with 
chorioadenoma destruens, a locally invasive form of 
chorioncarcinoma(78). The drug was administered in a 
single initial intravenous aose of 1.0 to 4.5 mg/kg, followed 
by 2.5 mg/kg at two week inuervals, each total biweekly 
dose being divided into five consecutive daily aoses. All 
tnree cases showed regression of pulmonary ©etastases, In 
one case of chorioncarcinoma each course oi drug therapy 
resulted in a decrease in urinary chorionic gonadotrophin 
. 
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and a regression of symptoms caused by metastatic involve¬ 
ment. The level of urinary chorionic gonadotrophin dropped 
from 4 million units/ml before therapy to 500 units/ml at 
the completion of therapy. No definite evidences of toxicity 
were found, although tne possibility of renal impairment, as 
measured by frequent determinations of blood urea nitrogen, 
contraindicates this drug in the presence of renal disease. 
Although hepatic>injury has not been observed, some gastro¬ 
intestinal toxicity and bone marrow depression has been seen. 
Decreased levels of chorionic gonadotrophin could not be 
correlated with the presence of excreted amethopterin. 
Li, Spencer, hertz, and Lubs noted in 1957 that the 
above three patients showed regression of metastases for 
8 to 14 months following amethopterin therapy. Three men 
with embryonal carcinoma of the testis responded to amethopterin 
therapy, but the response was less sustained. The marked 
variability in the spontaneous clinical course of trophoblastic 
tumors renders therapeutic evaluation difficult. The data 
presented by tnese authors constitutes unequivocal quantitative 
evidence, on the basis of decreased urinary cnorionic gonado¬ 
trophin titers to values approaching normal, that these tumors 
are susceptible to amethopterin(79). The dose used by Li et al 
was from 5 to 10 times the average adult dosage used in acute 
leukemia; drug toxicity was severe but not life-threatening(80). 
Some of the patients reported above are now showing 
relapses, however, with growth of cancer cells in the lungs. 
In some cases meiastases have been noted in the central nervous 
systeai(Sl). According to Welch, growth of cells in the lungs 
is attributable to the selection of a drug—resistant strain. 
The appearance of metastatic growth in the brain has stimulated 
investigations on intrathecal administration of amethopterin 
and also on the distribution ox this drug throughout the 
body, in particular its capacity to cross the bloon-brain 
barrier. Relapses in these patients may have been due to 
failure of the drug to reach the population of tumor cells 
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in the brain during the early period of growth when the 
tumor cells were more susceptible to the drug. Intrathecal 
therapy with amethopterin produces very few toxic effects 
upon the central nervous system* The limitanion oi dosage 
by this route depends upon the rate at which the drug 
leaves tne cerebrospinal fluid to enter the systemic 
circulation, tuereby producing toxic effects on the 
bone marrow and gastrointestinal oract, tissues previously 
described a3 having a special sensitivity to amethopterin. 
Li, Nixon, and Freeman, on the basis of work by 
Nichol and Welch(82), snowing that folic acid antagonists 
inhibit the synthesis of citrovorum factor in liver and 
also prevent its utilization by tissues in animals, studied 
the daily excretion of urinary citrovorum factor and correlated 
this with the tumor response in patients with trophoblastic 
tumors receiving amethopterin therapy(8b). In a o4 year 
old man with metastatic embryonal carcinoma and chorion- 
carcinoma to lungs and abdomen, the urinary citrovorum 
factor activity was at a constant low level before treatment; 
whereas administration of 25 to 35 mg of ametnopterin orally 
or intramuscularly daily for live aays resulted an a fivefold 
increase in urinary citrovorum factor activity; clinical 
improvement was not observed, however. A similar effect 
was observed in a d8 year old female with chorioncarcinoma 
with pulmonary metasxases, although the increase in urinary 
citrovorum factor activity seemed to diminish toward the 
end of each course and the rise on subsequent courses was 
less prominent than the preceding ones; tumor regression 
was obtained in ner case. 
It was shown that this increased citrovorum factor 
activity does not result iron tumor breakdown, normal tissue, 
as the result of drug toxicity, or drug contamination. 
Nichol and Welch proposed originally that folic acid 
antagonists have at least two actionss 1)inhibition of 
conversion of folic acid to folinic acia(citrovorum iactor), 
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and 2)inhibition of utilization of citrovorum factor 
(if blocked would result in an increase in citrovorum ' 
factor in the urine). These authors, when measuring 
urinary citrovorum factor after amethopterin administration 
to rats, have observed an increased excretion in some of 
the rats and have interpreted tnis as possible displacement 
of citrovorum factor(82). These cases apparently represent 
a similar displacement of citrovorum factor in humans by 
the administered amethopterin. 
C. Previous studies on the distribution of administered 
amethopterin and its permeability through the blood- 
brain barrier; rationale for synthesis of folic acid 
analogs. 
Fountain studied the distribution of amethopterin in 
normal mouse tissue following intravenous injection of tae 
drug and found that tae serum level was high initially(75 mjig/ml) 
and fell to zero after four hours. The relative concentrations 
of amethopterin in various tissues appeared to parallel the 
folic acid and citrovorum factor content, namely liver, 
kidney, and spleen in descending order. Arnethopterin-1ike 
activity was still appreciable in liver and kidney after 24 hours(S4). 
Whiteside et al studied tae distribution of intrathecal 
ametaopterin administered to dogs(73). At a dosage of 1.8 mg/kg 
it was shown that the initial cerebrospinal fluid drug level 
I 
of 15 mpg/ml fell to 56 mpg/ml after 43 hours, and that only 
a trace amount of amethopterin could be detected after 116 hours. 
Studies in man by Whiteside et al have been described in the 
previous section. 
Studies in man by Freeman indicate tnat ametnopterin is 
rapidly and totally absorbed after oral administration(85). 
The peak plasma level, reached after one hour in most cases, 
was proportional to the dose given. In plasma approximately 
50$> of the drug was found to be bound to plasma proteins. 
The distribution was limited to the extracellular space, 
and no demonstrable storage was observed in tne human after 
repeated small doses. After an intravenous dose of 18 mg 
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the plasma level quickly rose to 1.5 pg/ml, following which 
it rapidly fell, so that the concentration was less than 
0.5 jig/ml after tnree hours. The cerebrospinal fluid drug 
concentration in the same experiment reached 50 mpg/ml 
after three hours and did not rise above this value. 
After intravenous adniini strati on in man the drug was 
excreted very rapidly, an average of 99fo of the administered 
drug appearing in the urine within 12 hours. In the presence 
of renal failure, plasma levels were prolonged for a much 
greater period of time(85). 
Wollner, Lurphy, and Gordon in 1959 studied the 
distribution of amethopterin after intravenous injection 
into dogs, and found that only minute amounts of the drug 
entered the cerebrospinal fluid. No actual values were 
given for the cerebrospinal drug levels(86), Cerebrospinal 
fluid/serum concentration ratios at equilibrium were found 
to be less than 0.003 in dogs receiving constant intravenous 
infusions of drug. Intratnecal doses resulted in ii igh 
concentrations of drug being maintained in the cerebrospinal 
fluid for longer than 24 hours. Tne serum concentration 
of amethopterin fell rapidly after intravenous injection; 
following intrathecal administration, uowever, the serum 
concentration, although lower initially, was maintained 
for a longer period of time. From 60°jo to 80^ of administered 
amethopterin was recovered within 48 uours from the urine 
following intravenous or intrathecal injection. Simultaneous 
renal clearance studies revealed that amethopterin was 
excreted at a constant rate approximating that of creatinine. 
Freeman has commented on the appearance of a second 
substance, presumably a metabolite, in the urine of mice, 
rats, dogs, and all patients examined(except, patients with 
chronic leukemia) following the administration of &methopterin(87)• 
This secondary substance continues to appear in the urine 
for a period of four to twenty days after cessation of 
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drug administration. 
Freeman has reported that the capacity of anetnopterin 
to cross tne blood-brain barrier is extremely low(85^. 
Failure of the drug to attain appreciable levels in the 
brain is one possible reason for poor results observed in 
tne clinical treatment of cerebral manifestations of leukemia 
and chorioncarcinoma. 
Rationale for synthesis of folic acid analogs. 
It was hoped that tne introduction of slight modifications 
in the amethopterin molecule might confer upon it the ability 
to pass the blood-brain barrier while still retaining chemo- 
therapeutic activity. 
It nas long been known that, other factors being equal, 
drugs having a nigher lipid solubility penetrate into the 
brain more rapidly than tnose with a lower lipoid solubility. 
A number of isolated reports hint at the lipoid nature of 
tne blood-brain barrier. Experiments cited by Mayer et al 
indicate that for foreign compounds the blood-brain barrier 
behaves as a lipoid membrane, and that the permeability of 
the blood-cerebrospinal fluid and blood-brain barriers are 
identical with respect to drugs(l2). A widely accepted 
concept of the cell membrane describes tne boundary as a 
fat-like layer interspersed with small pores. Penetration 
of such a membrane could occur by several processes; 
1)lipid-soluble substances may passively penetrate into 
the cell by dissolving in the lipid-like phase; 2) non-polar 
substances, such as water and urea, may pass by free diffusion 
if tne pore' size is sufficient to aceomodaoe them; 3)in 
addition to these physical processes, special transfer 
m 0 chani s * *j s involving temporary combination with membrane 
constituents are required to transport inorganic ions, 
numerous endogenous substrates, and certain foreign compounds, 
among which antimetabolites are an important example. 
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Since nerve tissue contains lipids it is often stated 
tnat drugs gain access to the central nervous system by virtue 
of their solubility in brain lipids; this statement is often 
made in connection with the highly lipid—soluble thio- 
barbiturates, such as thiopental. There is no indication that 
1ipid-soluble drugs have any special predilection for brain 
tissue, suggesting that tne structural lipids do not nave 
the solubility characteristics of neutral fat. It is 
presumably the lipoid characteristics of tne blood-brain 
barrier and not of the brain tissue cells which regulate 
the entrance of drugs into the brain. 
Water-soluble organic compounds, such as sucrose, 
penetrate into' the brain very slowly. Highly ionized bases, 
such as tetraethylammonium and tubocurarine, penetrate with 
great difficulty. Brodie describes experiments which indicate 
tnat the rate of penetration of drugs into tne central 
nervous system is dependent upon the lipid solubility of 
the uncharged molecule^10). 
Preparation of the dimetnyl ester of amethopterin was 
thought to be one metnod of increasing the lipid solubility 
without altering appreciably that portion of tne molecule 
which is perhaps more intimately involved in blocking the 
folic-folinic acid biotransformation(Figure l). 
The diethyl ester of amethopterin was also prepared, 
since this substitution might increase the lipid solubility 
of tne compound over tnat ox tne dimethyl ester. Since 
much more difficulty was encountered in preparing tne 
diethyl ester in a soluble form suitable for injection 
than was experienced with tne dimethyl ester, it was thought 
tnat tne preparation of nigner analogs, such as the dipropyl 
ester, would engender such difficulties in solubilization 
in return for a negligible increase in lipid solubility 
tnat this line of approach was abandoned. 
The introduction of two cnlorine atoms into the 
j3-aminobenzoic acid ring of amethopterin is anotner possible 
way of increasing lipid solubility. In tnis case, nowever, 
more drastic effects on tne "enzymatically active’1 portion 
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of the molecule might be expected. Furthermore, the addition 
of a halogen atom to an organic acid can be expected to change 
tne extent of ionization. This is -Hell illustrated, by the 
change conferred upon acetic acid, which is only slightly 
ionized, by the substitution of three Chlorine atoms. 
Trichloroacetic acid exhibits such a high degree of ionization 
that it is classified as a strong acid. Rail et al commented 
on the effect of extent of ionization on degree of penetration 
of tne series of compounds, aniline, barbitone, amidopyrine, 
and salicylic acid. They noted that the degree of penetration 
into the brain could be inversely correlated with extent of 
ionization at ph 7.4. The distribution of certain of these 
drugs Detween blood and cerebrospinal fluid could be significantly 
and predictably altered by induction oi alkalosis or acidosis in 
the experimental animals(1). 
If the presence of tne chlorine atoms on the j)-aininobenzoic 
acid ring of amethopterin does increase the degree of ionization, 
the penetration of tne compound into the brain might oe expected 
to be hindered. It could be theorized, however, that the 
bulkiness of tne two Cxzlorine atoms present might increase 
the lipid solubility sufficiently to ofiset the effect of 
possibly increased ionization(Figure I). 
Goldin et al noted recently that 3',5•-uicnloroamethopterin 
was much more effective than amethopterin in extending the 
mean survival time of mice implanted with L121Q leukemia(88). 
Some of the mice nested were presumably cured and did not 
accept reinoculation with leukemic cells. The antileukemic 
action of this derivative could be reversed by tne concomitant 
administration of citrovorum factor. Other surviving mice 
showed partial immunity(89). This drug is being used in 
clinical trials at the present time(S8). 
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A. Materials and methods. 
The experimental protocol involvea collection of control 
specimens of plasma and cerebrospinal fluid, from dogs, intra¬ 
venous administration of a known nose of experimental drug, 
ana collection of samples of plasma and cerebrospinal fluid 
at intervals following tne drug injection. Tne plasma ana 
cerebrospinal fluid samples were tnen analyzed to determine 
tne drug levels present during each time interval. 
Healtny mongrel aogs weigning approximately 10 kg were 
anestnetized witn bO mg/kg nemoutal given intraperitoneally 
and were maintained in a&equate anesthesia during tne course 
of tne experiment by tne additional administration of 10 mg/kg 
nembutal as requirea. Eacn aog was placed in tne right lateral 
decubitus position with the dead and neck well supported and 
the nead moderately flexed. After shaving of tne suboccipital 
area of the neck, cerebrospinal fluid samples were obtained 
from tne cisterna magna by inserting a 00 mm #22 pediatric 
type lumbar puncture needle posteriorly just below tne 
inferior edge of tne occipital bone in the midline, and 
directing tne neeuie towara tne level oi tne hyoid bone 
palpated anteriorly(90,91). Forward progress of the needle 
should be carefully controlled by counter-pressure against 
tne neck; a sensation of decreased resistance, or ’’give,'1 is 
experienced when tne needle enters the cistern. At tnis 
point removal of the stylet usually yields a free flow of 
cerebrospinal fluid; if tnis does not occur, tne needle 
snould be rotatea sligntly or inserted 1 mm farther and 
recneckea. Once a free flow is estadlisnea tne neeale is 
taped in place, remaining in tne cistern tlirougnout the 
duration of tne experiment. Serial samples of cerebrospinal 
fluid are easily collected through this needle; it was not 
found necessary to use an intraluminal catheter. 
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About 1.0 ml of cerebrospinal fluid was removed at any 
one time. All samples containing red olooa ceils after 
centrifugation were aiscaraed, since cneir presence implies 
a leak in the blood-brain carrier. Samples of blood were 
taken at intervals tnrougnout tne experiment from superiicial 
leg veins. All springes used for blood collection were first 
rinsed with saturated sodium oxalate solution; also, 0.1 ml 01 
saturated sodium oxalate solution was added to eacn 5 ml blood 
sample collected. All blood samples were centrifuged 
immediately after collection for 10 minutes at 3000 SPM to 
remove formed elements, and the clear plasma as well as 
all cerebrospinal fluid samples were kept in an ice bath until 
tne time of analysis. Since aeparin nas been demonstrated 
to quencn fluorescence it was not used as an anticoagulant in 
tnese experiments. In tne event tnat tne initial cisternal 
tap was grossly or microscopically bloody, tne dog was rejected 
for further use on tnat day. 
After control samples ox cerebrospinal fluid and plasma 
nad been obtained and it nad been assured that no red blood 
ceils had been found in the cerebrospinal fluid, the required 
weight of drug was prepared for injection. Folic acid analogs 
were prepared by dissolving tne required weight of recrystallizett 
drug in 6 ml of 0.5N nydroculoric acid, with warming. Water 
was added to about 25 ml, tnen 5N sodium hydroxide dropwise 
to pH 4.0. The pH was never allowed to rise above 7.0 during 
tne procedure; it was found t^at most folic acid analogs 
formed a milky suspension unsuitable for injection above 
pH 4.0. The final volume of solution was about 30 ml. 
One gram of sulfadiazine was prepared for administration 
by dissolving two 0.5 gm tablets ox the drug in 10 ml ox 3.5^ 
sodium nyaroxiae, adding water to about 45 ml, tnen 4N 
hydrochloric acid dropwise to pii 9.0. The final volume of 
solution was about 50 ml. 
The drug solution to be administered was placed in a 
suitable syringe and injected over a fc>0 second period into 
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the right anterior foreleg vein. Tnis vein was avoiaea daring 
subsequent blooa sampling. Samples of blooa ana cerebrospinal 
fluid were obtained at 15 minutes, 50 minutes, and 180 minutes 
after tne injection of drug, and were treated as previously 
described for the control samples. In a few experiments, 
samples were obtained at 15 minutes, 30 minutes, and 50 minutes 
after drug administration. When all four samples of plasma 
and cerebrospinal fluid had been accumulated, tney were 
analyzed at the same time for the experimental drug. Tnere 
was no difficulty in maintaining tne position of the needle 
in the cisterna magna during the three-hour course of each 
experiment. All aogs were given 300,000 units of benzathine 
penicillin prophylactically; tney recovered quickly from 
tne anestnesia and remained in good condition following 
eacn experiment. 
Sulfadiazine was determined by the metuod of Bratton and 
Marshall, wnich involves diazotization of a aeproteinized 
solution of tne drag and coupling with N-naphthylethylenediamine 
to yield a colored product(9h). The procedure used was as follows: 
Procedure for Sulfadiazine: To 1 ml of plasma or 
cerebrospinal fluid, aaa 1 ml of 15^> trichloroacetic 
acid and centrifuge to remove protein. To 0.5 ml of 
the supernatant is added 1.0 ml of 0.1 jo sodium nitrite; 
after 3 minutes, 1.0 ml oi ammonium sulfamate is added. 
After 3 minutes 1.0 ml oi the aye, N~naphtuylethyleneaiawine, 
is added. Alter 20 minutes tne optical density of tnis 
product is determined at 540 rnp in a Beckman Spectro¬ 
photometer. 
A standard curve lor suliaaiazine 
of 1, 5, ana 10 pg/ml. 
Amethopterin and its analogs 
photoiluorometric metnoa modified 
The original metnod as outlined by 
was exactly linear at concentrations 
were determined by a 
after tnat of Freeman(93,94). 
Freeman is as follows: 
Procedure for Ametnopterin: Collect whole blood in oxalated 
tubes and separate plasma by centrifugation. Siphon plasma 
into a clean test tube. To 1 ml of plasma add 7 ml of 
distilled water and mix. Add 2 ml of 15/o tricnloroaceuic 
acid dropwise, with continuous stirring. Centrifuge. 
To 5 ml of tne supernatant aaa 1.0 ml of 3.24J& sodium 
hydroxide. Ada 0.1 ml of 5M acetate buffer pH 5 and mix. 
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Measure f lucreseence(a) . Add 0.05 ml 01 4°/o 
potassium permanganaoe, Wait 5 minutes. Ado. 0.1 ml 
3jo hydrogen peroxiae and mix; wait 3 minutes and 
measure fluorescence^B). 
Reading (B) minus reading (A) yields the fluor¬ 
escence increment; this is corrected oy means of a 
blank ueteriuinacion. Tne corrected increment is 
converted tp concentration of a...etnopterin ay means 
oi a standard curve. 
Since tne relationship Detween iluorescence increment 
and concentration of drug was not found to be linear using 
Freeman’s original metnod(Table I), modification of the 
metuod was necessary. 
Using soaium Hydroxide in a concentration of 3.2.4% as 
suggested by Freeman, it was noted tnat the i'inu,l pH of tne 
solution was 5.4 rather than 5.0, as it should be when 
reading (B) is tone. In audition, quenching of fluorescence 
was observed at pH 3.4(TabIe II). Amethopterin standards 
run without tne audition of trichloroacetic acid or sodium 
hydroxide had a final pH of 4.3 and a significant fluorescence 
increment, whereas tne addition of trichloroacetic acid and 
sodium Hydroxide depressed the final pH to o.4 and resulted 
in a negligible fluorescence increment. 
An optimum pH for the procedure was determined by 
titrating 1 microgram samples of ametnopterin with sodium 
nyuroxide, and determining the iluorescence reauings at 
increments of 0.1 pH unit(Table III). It was apparent that 
a pH oi 5.0 represented an optimum value for the analysis, 
since the fluorescence is high at this point and the pH 
still does not approach neutrality, with the possible 
precipitation of manganese dioxide at alkaline pH values. 
Accordingly, an electrometric titration was carried 
out to determine the concentration of sodium nyuroxide 
required in tne analysis to achieve a filial pH of 5.0. 
The titration required 8.4 ml of 0.1G64N sodium hydroxide, 
or 0.89376 milliequivalent of base, to bring the pH to 5.0. 
This represents 1.0 ml of o.dft sodium hydroxide, rather than 
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TABLE X 
STANDARD CUHVL USING FKKEfAN'S ORIGINAL MET BCD 
Concentration of Ametnopterin Fluoresceace Increment 
100 m|ig/ml 0.05 
1000 m|ig'/ml 0.46 
14000 mjig/ml 3.96 
Deprofexnxzed amethopterxn standards were treated 
with I ml of 3.24fo sodium 
5M acetate buffer pli 5.0. 
taken, the solutions were 
4/a potassium permanganate 
peroxide, and reading (B) 
hydroxide and 0.1 ml of 
After reading (A) was 
treated witu 0.05 mi of 
and 0.1 mi of 3°/o hydrogen 
was taken. 
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EFFECT OF ADDITION OF 3.24°jo SODIUM HYDROXIDE AND 
TRICHLOROACETIC ACID ON FINAL pH AND FLUORESCENCE 
INCREMENT(EACH VALUE REPRESENTS TWO EXPERIMENTS) 
Ametnopterin Concentration Buffer TCA+NaGH aaaea Increment Final pH 
0 0.1 ml -OoGl 4.3 
1 Jlg/Ell 0.1 ml — +0.41 4.3 
0 0.1 ml + -0.02 3.4 
1 ng/ml 0.1 ml + +0.15 3.3 
AmetHopterin standards in water solution were treated with 
0.1 ml of butfer^controls), or 0.1 ml ox buffer + 1 ml 15$> 
trichloroacetic acid(TCA) + 1 ml 3.24c/o sodium hydroxide 
(experimental). After reading (A), 0.05 ml of 4 ’jo potassium 
permanganate and 0.02 ml of 3)o hydrogen peroxide we»e addea, 
and reaaing ^B) was taken. 
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TABLE III 
DETERMINATION OF OPTIMUM pH FOR ANALYSIS 






6. 0 1.01 
0.1 1.26 
To a 1 p.g sample of amethopterin in water solution 
were added 1 ml of 13cJo trichloroacetic acid and 1 ml 
of 3.5fo sodium hydroxide$ 0.1 ml of 5M acetate buffer 
pH 5.0 was tnen added. After reading (a) was taken 
0.05 ml of 4% potassium permanganate and 0.02 ml of 
3% hydrogen peroxide were added. Pleading (B) was 
taken. Reading (B) minus reading (a) yields the 
fluorescence increment shown above. The solution 
was then titrated electrometrically with 0.1 N sodium 
hydroxide in increments of 0.1 pH unit. A fluor¬ 
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3.241° as suggested, by Freeman. The use of this concentration 
of sodium hydroxide resulted in a significant fluorescence 
increment and the desired end pH ox 5.0 to 5.1(Table IV), 
After the step in tue analysis involving tne addition 
of 0.1 ml of 3jo hydrogen peroxide, a brown precipitate of 
manganese dioxide was occasionally observed in some of tne 
plasma samples; values obtained with such samples were inaccurate. 
The precipitate could be dissolved by the addition of anotner 
0.1ml of 3°jo hydrogen peroxiae. The use of 0.2 ml of 3% 
hydrogen peroxide, as opposed to 0.1 ml, has no effect on 
the fluorescence increment(Table V). The routine use of 
0.2 ml of 3% hydrogen peroxide gave stable reproducible 
values, and no difficulties were encountered with manganese 
dioxiue precipitates. 
In addition, fluorescence increment values obtained with 
water solutions of amethopterin were not comparable with those 
obtained with plasma solutions of the same drug. It was 
discovered that dilution of plasma samples 1:10 before analysis 
resulted in experimental values closely approximating those 
obtained in standard solutions of ametnopterin in water. 
Fluorescence increment values with undiluted plasma averaged 
1.0 times tnose obtained with plasma diluted 1:10 or with 
water, using identical concentrations of ametnopterin(Table Vi). 
Amethopterin could be estimated to Ibfo in water solution 
and plasma diluted 1:10, wnen known quantities were added 
to each. It could be detected accurately in concentrations 
as low as 40 mug/ml(Table VII). Two cerebrospinal iluid 
standards at 80 mpg/ml were accurate witnin 0fo and 25cjo respectively. 
The method of determination finally adopted was as xoliows: 
ANALYTICAL METHOD FOR THE DETERMINATION OF FOLIC 
ACID ANALOGS IN PLASiiiA AND CEREBROSPINAL FLUID 
Procedure: To G.l ail of plasma or 1.0 ml of cerebro¬ 
spinal fluid, add 7.9 ml or 7,0 ml respectively of 
distilled water and mix thoroughly. Add 2,0 ml of 15fo 
trichloroacetic acid dropwise, with continuous stirring. 
Tae mixture is then centrifuged at 10,000 PPM for 15 
minutes to remove tne precipitated protein. To 5 ml of 
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TABLE IV 








—0.02 b. 1 
+ 1» 45 5.0 
+ 1.51 5.0 
To lieproteinizea solutions of amecnopferin ¥ere added 
1 ml of d,bfo sodium nydroxide ana 0.1 ml of 5M acetate 
buffer pH 5.0. After reading (A) was taken, 0.05 ml 
of 4/e potassium permanganate and 0.02 ml oi 6% hyarogen 
peroxide were aaded. Reading' (B) and the final pH 
were then aecermined. 
Tue difference in fluorescence increment values 
in tables II ana IV is aue to the different concentrations 
of sodium nydroxide used in the two instances. In audition 
uaily fluctuations in the sensitivity of the spectrofluoro— 
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TABLE V 
EFFECT OF DIFFERENT VOLUMES OI-' 3 jo HYDROGEN 
PEROXIDE ON FLUORESCENCE INCEE&iEiJT 
Ametaopterin Concentration Volume of Peroxiae Fluorescence 
1 pg/rnl 0.1 ml +0.44 
1 pg/ml 0.1 ml +0.42 
1 pg/rnl 0.2 ml •+• 0 • 45 
1 pg/ial 0.2 ml +0.42 
To standard solutions of ametnopterin in water ■wo,s 
added 0.1 ml oi 5M ucet&te buffer pH 5.0, After 
reading (a), 0.05 ml of 4°/o pot„ssxum permanganate 
and eitner 0.1 or 0.2 ml of 3% hydrogen peroxide 
were added. Reading (B) was taen determined. 
A . 
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TABLE VI 
COMPARISON OF FLUORESCENCE INCREvJSNT VALUES OBTAINED 
WITh UNDILUTED PLASMA, PLASMA DILUTED 1:10,AND WATER 
^aietnopterin Concentracion\mpg/ml) Medium Fluorescence increment 
80 water 0.08 
80 undiluted plasma 0.14 
80 undiluted plasma 0.14 
80 plasma 1:10 0.08 
80 plasma 1:10 0.08 
160 water 0.17 
160 undiluted plasma 0.21 
160 undiluted plasma 0.25 
160 plasma 1:10 0.14 
160 plasma 1:10 0.15 
320 water 0.35 
320 undiluted plasma 0.54 
320 undiluted plasma 0.50 
320 plasma 1:10 0 0 0 
320 plasma 1:10 0.32 
Deproteinizea standards were treated with 1.0 ml 
of 3.6^ sodium hydroxide and 0.1 ml of 5M acetate 
buffer pli 5.0. After reading (a) was taken, 0.05 ml 
of 4°jo potassium permanganate and 0.02 ml of Sf> 
hydrogen peroxide were added, and reading (B) was 
taken(modified method of analysis). 
, 
. 







RECOVERY OF AIvxEIirlOFTERIN FROM WATER, 
CEREBROSPINAL FLUID, AND 1:10 PLASMA 
Medium Quantity present(mpg/mlj Quantity recovered(mpg/inl) jolifSaren 
water 40 40 0 jo 
water 40 40 0 jo 
water 80 80 0 jo 
water 80 70 
CO 8 
water 80 80 0 jo 
water 80 67 -16 jo 
water 80 80 0 jo 
water 80 93 + 16 jo 
water 80 70 i co
 
water 80 90 + 13 jo 
water 160 170 + 7 jo 
water 320 320 0 jo 
water 320 258 -18 jo 
water 320 305 - 5 jo 
water 320 294 - 8 jo 
water 320 346 + 8 jo 
water 1000 990 - 1 jo 
plasma 80 88 + 10 jo 
plasma 80 70 -13 jo 
plasma 80 80 0 jo 
plasma 160 150 - 7 jo 
plasma 160 160 0 jo 
plasma o 20 630 + 3 jo 
plasma 320 320 0 jo 
plasma 320 312 - 3 jo 
plasma 1000 1000 0 jo 
plasma 1000 1160 + 16 jo 
plasma 1000 1120 + 12 jo 
cerebrospinal Fluid SO 80 0 jo 
cerebrospinal fluid 80 100 +25 jo 
"teiiivr 
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tne supernatant in a separate tube acid 1.0 ml 
of sodium hydroxide and 0.1 ml oi' 5M acetate 
buffer pK 5.0. After thorough mixing the fluor¬ 
escence^ reading A) is determined in a spectrofluoro- 
photometer with activation wavelength 370 mp ana 
fluorescence wavelength 450 cap. To the mixture is 
then added 0.05 ml of 4/o potassium permanganate, 
and the solution is mixed thoroughly and allowed, 
to stand for five minutes. Alter this period of 
time lias elapsed, 0.2 ml of freshly prepared 3°/o 
hydrogen peroxide is added to remove the excess 
permanganate. The solution is luixeu iv0 ii and allowed 
to stand for three minutes. The fluorescence is 
again determined as before(reading B). 
Interpretation; Same as Freeman's metnod(page 24)» 
Comments on the experimental procedure: 
1. The activating wavelengtn is variously given in the 
literature as between 280 rap and 370 mp, and tne fluor¬ 
escent wavelength jetween 450 mp and 470 mp(85,94). 
Preliminary experiments indicated that the optinur 
wavelengths were 370 mp activating and 4o0 mp fluorescent. 
2. All solutions suould be freshly mane and carefully 
protected from air, since the increment is constant 
only if the ph is held within rather close limits. 
The ofi hydrogen peroxide is made just before use by 
1:10 dilution of 30Jo hydrogen peroxide. The buffer 
is prepared by adding 70 ml ox 5M sodium acetate solution 
to 30 ml of 5M acetic acid, tnen adding glacial acetic 
acid dropwise until a 1:10 dilution of the buffer nas 
a pH of 5.0. 
3. The second fluorescence reading(B) should be taken 
within 10 seconds after filling tne cuvette with the 
solution, since oxygen bubbles are released at this 
point, causing a narked increase in tne reading. If 
more time is needed, the cuvette suould be gently 
tapped to eliminate bubbles. 
4. Standard solutions of a^etnopterin at various concen¬ 
trations were run with each experimental analysis, since 
there were slight day to day fluctuations in tne experimental 
readings obtained lor given concentrations ox drug. 
5. If anj solutions appear cloudy after centrifugation, 
tney should be recentrifuged, since even the slightest 
turbulence causes a marked increase in tne xluorescence 
reading. 
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6. Not more than 12 to 15 samples suould be run at one time, 
since the fluorescence may decrease if tne solutions are 
allowed to stand xor too long a period of time before 
reading. 
7. Toward tne latter part of the work a new Xenon light source 
was installed in tne spectrofluorophotometer, resulting in 
nrucn higher sensitivity readings for given concentrations of 
ametnopterin. At tnis time, concentrations as low as 10 mpg 
could be detected. 
The standard curve for conversion of fluorescence increment 
to concentration of a^etuopterin was prepared by dissolving 
10.00 +_ 0.001 mg of drug(weignea on a microoalance) in 100 ml 
of distilled water; tnis solution contained 100 |ig/ml. 
Reference standards were prepared by diluting this stock 
solution 1:10, 1:100, 1:1,000, and 1:10,000. The standard 
curve obtained by analysis of tnese solutions according to 
tne method described above yields an exactly linear plot of 
fluorescence increment vs concentration(Taole VIII; Figure II)a 
Standards run with eacn daily experiment were checked 
against tne standard curv% for verification of tne correctness 
of the daily experimental procedure before oeing used to 
convert increment readings to concentrations of drug. 
The results of analysis of the various analogs ure 
reported in terms of amecaopterin concentration. Drugs used 
10 
experimentally were aneunopterin(4—amino-N -metaylpteroyl— 
glutamic acid), and dimetnyl and aietuyl esters of ametnopterin, 
* 




synthesized by A. Eisenfeld 
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TABLE VIII 
data for standard curve 
Ametuopterin Conceatration^iupg/ml) Increment K(Increment/Concentration) 
0 0 
10 0.02 0.002 
100 0.19 0.0019 
1000 1.94 0.0019 
10000 18.94 0.0019 
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FIGURE II 
STANDARD CURVE FOR AaBFrOETERIN 
Log ametnopterin concentration in 
mng/ml vs log iluorescence increment 
+2 
-2 ‘-1-1-1- 
2 3 4 
LOG AMETHOPTERIN CONCENTRATION IN my/ml 
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B. Results and aiscussion 
No untowara reactions were observed to any of tne arugs 
usea, except that lor about ten minutes following injection 
of ametiiopteriii or its analogs tne aegree 02 anesthesia 
ligntenea, occasionally requiring the administration 02 
additional nembutal to maintain adequate anesthesia. 
In oraer to test tne valiaity of tne experimental method 
and the method of sampling, suifauiazine, a arug known to 
penetrate the blood-brain barrier, was administered in high 
dosage(lOO mg/kg) intravenously(1,25). This arug was toana 
to penetrate quickly into tne cerebrospinal fluid, being 
detectable at levels of 1.2 jig/rnl after lo minutes, <. i pg/ral 
after oO minutes, and lo.b jig/ml after 180 minutes(Table XX)* 
The plasma concentration of this arug over the same time 
interval was decreasing from 48 jig/ml to ol pg/ml. It is 
thus apparent chat one experimental proceuure aescribed 
previously provides a valid screening metnoa in testing 
experimental arugs for penetration into the cerebrospinal fluid. 
Amethopterin was seen to penetrate very slightly into 
one cerebrospinal fluid when mjectea intravenously in a 
uosage of 5 mg/kg(Table IX). This confirms the work of 
Woilner et al, although they aid not state tne exact level 
of drug found in the cerebrospinal fluid in their experiments. 
When amethopterin was administered in a aosage of 10 mg/kg, 
tne drug was undeoecfaole in the cerebrospinal fluid after 
15 minutes. Tne trace level seen with the lower dosage is 
at the lower limit of detectability of tne analytical 
method, and it may well be chat slight variations in the 
procedure 01 administration of arug and/or analysis may 
account xor the failure to 2mu tne drug in the cerebro¬ 
spinal fluid at tne higher uosage level. 
The rationale for tne preparation of the dimethyl 
ester of amethopterin has already teen aescribed. In a 
preliminary experiment, the dimethyl ester of amethopterin 
was found to penetrate into the cerebrospinal fluid to the 
( 
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extent oi 32 m|ig/ial 30 minutes alter administration of 
6 mg/kg. When tne experiment was repeated, at a nosage of 
10 mg/kg, however, tue compound was not detectable in tne 
cerebrospinal fluid(Table IX). 
Tne ciietuyl ester was also aominis cered to aogs in 
a similar dosage, and failed to penetrate into tne cerebro¬ 
spinal fluid at tne same that appreciable plasma concentrations 
were present. 
When 3'jb’-dicnloroametnopterm was injected intravenously 
into dogs in a dosage oi 10 mg/hg, slight out measurable 
amounts were detectable in the cerebrospinal iluia alter oO 
minutes, in repeated experiments. This xinning supports tne 
clinical trials presently being conducteu with tnis urug. 
It was initially planned to test other analogs of 
loiie acid ior penetration through tue blood-brain barrier, 
but these proposed experiments nan to be aoanuonea, since 
other compounds were unavailable. 
The rapid decline in plasma levels seen during the ^irst 
three hours after administration oi tnese drugs is in agreement 
witn tne work previously published by Fountain, in wnicn a 
high initial plasma level of ametuopierin fell to almost 
zero after four hours. 
Failure of the dimethyl and diethyl esters to penetrate 
into the cerebrospinal fluid in some of these experiments 
may have been true to rapid nydrolysis oi one compounds, 
particularly by tne liver. Preliminary observations indicated 
tnat rapid hydrolysis of dimetnylamethopterin was observed in 
blooa, brain, and especially the liver. 
These experiments no not represent an attempt to measure 
the rates of penetration ox these drugs into the cerebro¬ 
spinal fluid, since a constant plasma level was not maintained 
during the course ox each experiment,. These experiments were 
designed as a screening method useful in finding a compound 
Which would penetrate tne cerebrospinal fluid readily and in 
nigh concentration, had such a compound been discovered, 
rate studies would nave been carried out. 
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Table ix 
PLASLA AND CEREBROSPINAL FLUID DRUG LEVELS AFTER 
INTRAVENOUS ADMINISTRATION INTO DOGS 
Drug Bose^mg/kg) Plasma Levels (jig/ml) csf : Levels (mjig/nil) 
0 15 60 180(min^ 0 15 ■ 30 60 180 
Ametaopterin 5 0 trace 0 0 
Amethopterin 10 0 16.2 9.5 3.6 0 0 * * 
Bimethylametnopterin 5 0 trace 32 trace 
Dimetnylametnopterin 10 0 5.5 1.8 1.2 0 0 0 0 
Dietnylametnopterin 10 0 5. 0 1.6 * 0 0 0 0 
DicAloroametuopterin 10 0 5.L 1.4 0 0 16 32 16 
BicAloroametnopterin 10 0 11.0 3.6 0.8 0 0 30 10 
Sulfadiazine 100 0 48 41 31 0 1200 7700 15? 600 
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Tne study of penetration Ojl drugs into tne train is 
presently a iertile iield for experimental investigation. 
It is nopeu tuat tne analytical metLous and screening 
procedures presented nere 'id.ll enable iuture investigators 
to test experimental analogs of iolic acid, as well as otrier 
newly developed cnemotnerapeutic agents, xor penetration 
onrougn tne blood—brain barrier. 
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III. SUMi&RY AND C ONCLUSI0NS 
1. Folic acid analogs can be determined with quantitative 
accuracy in blood and cerebrospinal fluid, in concentrations 
as low as 40 mp.g/ml. Tiie method of analysis presented 
yields a constant linear relationship be tureen fluorescence 
increment and concentration of compound between tue range 
40 mpg/ml to 10 ug/ml. The experimental error of the 
analytical metnod was found to be _+ 16%(Table VII). 
Concentrations in the range of 5 mpg/ml to 40 mpg/ml 
are detectable but the values obtained are subject to 
a higher degree of error. 
2. A method is presented for the easy removal of samples of 
cerebrospinal fluid from dogs without trauma or contamination 
of tne samples by blood leakage. 
3. An experimental protocol is described for screening 
proposed chemotherapeutic agents, in order to determine 
penetration of the agents from tne blood into the cerebro¬ 
spinal fluid. Tne validity of this procedure is verified 
by demonstration of tne rapid penetration of sulfauiazine, 
a compound known to peneorate the blood-brain barrier easily. 
4. Amethopterin, dimethylamethopterin, dietnylametliopterin, 
and 31,5'-dichloroametnopterin were infused intravenously 
over a period of one minute in a aosage of 10 mg/kg into 
healthy nogs. Plasma levels were determined at 15 minutes, 
60 minutes, and 180 minutes after infusion of drug, 
highest plasma levels measured lor all iour compounds 
were attained at the 15 minute time interval, with a 
gradually decreasing plasma concentration over the next 
165 minutes. 
6. Ametnopterin penetrated into the cerebrospinal fluid in 
trace levels(about 7 mng/ml) 15 minutes after intravenous 
infusion of 5 mg/kg of drug. 
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6. Esterification of the glutamic acid moiety of ametnopterin 
improves tiie penetration over that ox the parent compound^ 
30 minutes after intravenous administration of 5 mg/kg^fd'!thetV»ybw€.1i 
58 mjig/ml -were xounu in ohe cerebrospinal fluid. Neitner 
dimethylamethopterin nor dietnylametnopterin penetrated 
into the cerebrospinal fluid at a aosage of 10 mg'/kg. 
Possible reasons for tnese findings are discussed. 
7* The compound 5 ’ ,o'-aichioroaaietnopterin was found to 
penetrate into the cerebrospinal fluid, being detectable 
tnere in low concentrations. At a uose of 10 mg/kg of 
drug, tne maximum concentration of drug reached in the 
cerebrospinal fluid was 30 mpg/ml 50 minutes after 
infusion of drug. Tne plasma level of drug at this time 
interval was o.o |ig/ml. 
8. Various factors wnicn influence the penetration oi drugs 
into the brain are reviewed. It appears essential that 
tne medicinal cnemst synthesize drugs with a high 
organic soivent/water distribution ratio at pH 7.4, 
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